Patents by Inventor Geertruida M. Veldman
Geertruida M. Veldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8092798Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.Type: GrantFiled: May 24, 2010Date of Patent: January 10, 2012Assignee: Wyeth LLCInventors: Jane Aghajanian, William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
-
Publication number: 20110275790Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 29, 2009Publication date: November 10, 2011Applicants: MEDIMMUNE LIMITED, WYETHInventors: DAVINDER S. GILL, JING LI, GEERTRUIDA M. VELDMAN, LYNETTE A. FOUSER, VIIA VALGE-ARCHER, DAVID C. LOWE, CAROLINE S. RUSSELL, SUZANNE E. COHEN, ALBERT G. THOM, RALPH R. MINTER
-
Publication number: 20110243953Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: ApplicationFiled: December 7, 2009Publication date: October 6, 2011Applicants: Wyeth, Medlmmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 7927835Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: GrantFiled: July 3, 2008Date of Patent: April 19, 2011Assignee: Genetics Institute, LLCInventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Patent number: 7901684Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: March 8, 2011Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 7883704Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: December 22, 2006Date of Patent: February 8, 2011Assignee: Abbott GmbH & Co. KGInventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Publication number: 20110020330Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicant: WyethInventors: Jane Aghajanian, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein, William J. Dunham
-
Publication number: 20100184960Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: January 29, 2010Publication date: July 22, 2010Applicants: Wyeth, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Patent number: 7731961Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.Type: GrantFiled: April 19, 2007Date of Patent: June 8, 2010Assignee: WyethInventors: Jane Aghajanian, William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
-
Patent number: 7666421Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: December 5, 2005Date of Patent: February 23, 2010Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 7655763Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: July 13, 2007Date of Patent: February 2, 2010Assignees: Wyeth, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 7638604Abstract: Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).Type: GrantFiled: June 22, 2004Date of Patent: December 29, 2009Assignee: Genetics Institute, LLCInventors: Jing Li, Xiang-Yang Tan, Kathleen N. Tomkinson, Debra D. Pittman, Geertruida M. Veldman, Lynette Fouser
-
Patent number: 7615213Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: June 9, 2005Date of Patent: November 10, 2009Assignee: WyethInventors: Marion T. Kasaian, Lioudmila Tchistiakova, Geertruida M. Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20090269302Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: February 25, 2009Publication date: October 29, 2009Applicant: ABBOTT GMBH & CO. KGInventors: Jochen SALFELD, Michael ROGUSKA, Michael PASKIND, Subhashis BANERJEE, Daniel TRACEY, Michael WHITE, Zehra KAYMAKCALAN, Boris LABKOVSKY, Paul SAKORAFAS, Geertruida M. VELDMAN, Amy VENTURINI, Angela WIDOM, Stuart FRIEDRICH, Nicholas W. WARNE, Angela MYLES, John Gawain ELVIN, Alexander Robert DUNCAN, Elaine Joy DERBYSHIRE, Sara CARMEN, Stephen SMITH, Thor Las HOLTET, Sarah Leila DU FOU
-
Patent number: 7563760Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: GrantFiled: August 21, 2001Date of Patent: July 21, 2009Assignee: Genetics Institute, LLCInventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Publication number: 20090175857Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: October 16, 2008Publication date: July 9, 2009Applicant: Abbott GMBH & Co., KGInventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Patent number: 7531175Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: November 12, 2004Date of Patent: May 12, 2009Assignee: Genetics Institute LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Publication number: 20090104180Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: ApplicationFiled: July 3, 2008Publication date: April 23, 2009Inventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Patent number: 7504485Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: July 1, 2004Date of Patent: March 17, 2009Assignee: Abbott GmbH & Co., KGInventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Publication number: 20090028883Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: ApplicationFiled: July 3, 2008Publication date: January 29, 2009Inventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw